Loading stock…

Fisher & Paykel Healthcare Corporation Limited (FPH) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Fisher & Paykel Healthcare Corporation Limited

FPHMarket cap $15BPrice $26.4

Country🇳🇿New Zealand

SectorHealthcare

IndustryHealthcare Equipment

Makes breathing devices and humidifiers for respiratory care, sleep apnea, and surgery patients worldwide. This New Zealand company turns hospital breathing tubes into a growth machine, selling into over 120 countries with margins most medtech rivals envy.

In Bastion Portfolios?

52W Return+31%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+10%7

Revenue Forecast

Rev CAGR (1y)+9%6

Rev CAGR (3y)+12%7

Rev CAGR (5y)+10%7

Earnings Forecast

EPS Growth Y+1+18%8

EPS Growth Y+2+15%8

EPS Growth Y+3+16%8

Quality

Margins

EBIT Margin28%9

Net Income Margin20%8

Free Cash Flow Margin21%8

Debt

Net Debt/EBITDA-0.410

Efficiency

ROE23%8

ROA17%10

Earnings Stability55

GEAR+VERY STRONG91

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)481

P/E Ratio (Forward 3y)371

P/BV12.91

EV Multiples

EV/EBITDA Fwd301

EV/EBIT Fwd362

Yield

Free Cash Flow Yield1.8%4

Dividend Yieldna–

Momentum

Short term

1 month return+4%9

3 month return+13%9

YTD return+24%8

Mid term

Price vs 52wHigh100%10

1 year return+23%7

Long term

3 year return+118%8

5 year return+66%6

Risk Shield

Price Risk

Beta0.48

Volatility26%8

Free Cash Flow

Free Cash Flow Margin21%8

Free Cash Flow Yield1.8%4

Quality

ROCE29%10

Earnings Stability55

Net Debt/EBITDA-0.410

02Growth

Is it actually growing, and how fast?

FPHFisher & Paykel Healthcare Corporation

Revenue FY26$1.3B

GROWTH RATING↗

STRONG68 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+10%7

Revenue, next 1Y+9%6

Revenue, next 3Y, CAGR+12%7

Revenue, next 5Y, CAGR+10%7

EARNINGS FORECAST▾SCORE

EPS growth, FY27E+18%8

EPS growth, FY28E+15%8

EPS growth, FY29E+16%8

GROWTH ASSESSMENT

STRENGTHS

It out-grows 68% of companies worldwide.

Revenue grew 10%/yr over the last 3 years, ahead of 60% of companies worldwide.7/10

Revenue is set to grow 12%/yr over the next 3 years, ahead of most of the market.7/10

Revenue grew 10%/yr over the last 3 years and is set to keep growing around 12%/yr.

The runway holds up: revenue is set to grow 10%/yr over five years.7/10

Earnings are set to grow in step with sales (EPS about 16%/yr vs revenue 12%/yr).

WATCH

None flagged.

WEAKNESSES

None flagged.

BOTTOM LINE

Steady Grower

A top-tier grower.

03Price Momentum

Is the market behind it right now?

FPHFisher & Paykel Healthcare Corporation

Total return Current344%

Price return Current289%

MOMENTUM RATING↗

VERY STRONG90 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+4%9

3-month return+13%9

YTD return+24%8

MID & LONG-TERM▾SCORE

% of 52-week high100%10

1-year return+23%7

3-year return+118%8

5-year return+66%6

MOMENTUM ASSESSMENT

STRENGTHS

Strong long-term results. Long-term holders have seen +118% over three years and +66% over five, ahead of 60% of the market.

It's up 23% over the past year, now sitting right at its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+4%), over three months (+13%) and so far this year (+24%).

WATCH

None flagged.

WEAKNESSES

None flagged.

BOTTOM LINE

Momentum Leader

Short- and long-term returns both rank among the best globally, and the stock trades near its highs. The market is fully behind it — a core fit for momentum strategies.

04Value

Are you paying a fair price for it?

Stop guessing on Fisher & Paykel. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

FPHFisher & Paykel Healthcare Corporation

Revenue FY26$1.3B

GROWTH RATING↗

STRONG68 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+10%7

Revenue, next 1Y+9%6

Revenue, next 3Y, CAGR+12%7

Revenue, next 5Y, CAGR+10%7

EARNINGS FORECAST▾SCORE

EPS growth, FY27E+18%8

EPS growth, FY28E+15%8

EPS growth, FY29E+16%8

GROWTH ASSESSMENT

STRENGTHS

It out-grows 68% of companies worldwide.

Revenue grew 10%/yr over the last 3 years, ahead of 60% of companies worldwide.7/10

Revenue is set to grow 12%/yr over the next 3 years, ahead of most of the market.7/10

Revenue grew 10%/yr over the last 3 years and is set to keep growing around 12%/yr.

The runway holds up: revenue is set to grow 10%/yr over five years.7/10

Earnings are set to grow in step with sales (EPS about 16%/yr vs revenue 12%/yr).

WATCH

None flagged.

WEAKNESSES

None flagged.

BOTTOM LINE

Steady Grower

A top-tier grower.

03Price Momentum

Is the market behind it right now?

FPHFisher & Paykel Healthcare Corporation

Total return Current344%

Price return Current289%

MOMENTUM RATING↗

VERY STRONG90 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+4%9

3-month return+13%9

YTD return+24%8

MID & LONG-TERM▾SCORE

% of 52-week high100%10

1-year return+23%7

3-year return+118%8

5-year return+66%6

MOMENTUM ASSESSMENT

STRENGTHS

Strong long-term results. Long-term holders have seen +118% over three years and +66% over five, ahead of 60% of the market.

It's up 23% over the past year, now sitting right at its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+4%), over three months (+13%) and so far this year (+24%).

WATCH

None flagged.

WEAKNESSES

None flagged.

BOTTOM LINE

Momentum Leader

Short- and long-term returns both rank among the best globally, and the stock trades near its highs. The market is fully behind it — a core fit for momentum strategies.

04Value

Are you paying a fair price for it?

Stop guessing on Fisher & Paykel. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community